Quantum Leap Healthcare Collaborative and Ambrx Biopharma have selected the latter’s antibody drug conjugate (ADC), ARX788, for a new investigational treatment arm in the Phase II I-SPY 2.2 TRIAL to treat HER2-positive breast cancer in the neoadjuvant setting. 

An anti-HER2 antibody drug conjugate (ADC), ARX788 is being analysed widely in breast cancer, gastric / gastroesophageal junction (GEJ) cancer and various other solid tumours. 

The adaptive trial is sponsored by Quantum Leap and assesses developing targeted agents to combine them with less toxic chemotherapeutic regimens or to completely replace cytotoxic chemotherapy. The company expects to commence subject enrolment in the ARX788 arms in May this year.

In the trial, ARX788 will be assessed as a single agent and along with the programmed cell death protein 1 (PD-1) targeting checkpoint inhibitor, cemiplimab, in subjects with HER2-positive early-stage breast cancer in the neoadjuvant setting. 

I-SPY 2.2 follows the I-SPY 2 TRIAL, designed to quickly analyse encouraging experimental therapies and detect the most effective ones in specific patient subgroups depending on molecular characteristics.

Ambrx Biopharma board chairman president and CEO Feng Tian said: “I am thrilled that Quantum Leap has selected Ambrx’s antibody drug conjugate, ARX788, to be evaluated in the I-SPY 2.2 TRIAL. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are encouraged by the favourable anti-tumour activity and safety profile of ARX788 for the treatment of early-stage breast cancer. 

“It may provide a less toxic treatment option for patients through the precision conjugation of cytotoxic payloads targeting HER2 receptors.”

In April last year, Quantum Leap concluded subject enrolment in the icatibant arm of the I-SPY COVID Trial analysing various agents to treat critically ill patients.